Literature DB >> 25251388

LRRK2 pathobiology in Parkinson's disease.

Ian Martin1, Jungwoo Wren Kim, Valina L Dawson, Ted M Dawson.   

Abstract

Mutations in the catalytic Roc-COR and kinase domains of leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial Parkinson's disease (PD). LRRK2 mutations cause PD with age-related penetrance and clinical features identical to late-onset sporadic PD. Biochemical studies support an increase in LRRK2 kinase activity and a decrease in GTPase activity for kinase domain and Roc-COR mutations, respectively. Strong evidence exists that LRRK2 toxicity is kinase dependent leading to extensive efforts to identify selective and brain-permeable LRRK2 kinase inhibitors for clinical development. Cell and animal models of PD indicate that LRRK2 mutations affect vesicular trafficking, autophagy, protein synthesis, and cytoskeletal function. Although some of these biological functions are affected consistently by most disease-linked mutations, others are not and it remains currently unclear how mutations that produce variable effects on LRRK2 biochemistry and function all commonly result in the degeneration and death of dopamine neurons. LRRK2 is typically present in Lewy bodies and its toxicity in mammalian models appears to be dependent on the presence of α-synuclein, which is elevated in human iPS-derived dopamine neurons from patients harboring LRRK2 mutations. Here, we summarize biochemical and functional studies of LRRK2 and its mutations and focus on aberrant vesicular trafficking and protein synthesis as two leading mechanisms underlying LRRK2-linked disease.
© 2014 International Society for Neurochemistry.

Entities:  

Keywords:  GTPase; Rps15; alpha-synuclein; kinase; neurodegeneration; protein translation

Mesh:

Substances:

Year:  2014        PMID: 25251388      PMCID: PMC4237709          DOI: 10.1111/jnc.12949

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  102 in total

1.  Translation initiator EIF4G1 mutations in familial Parkinson disease.

Authors:  Marie-Christine Chartier-Harlin; Justus C Dachsel; Carles Vilariño-Güell; Sarah J Lincoln; Frédéric Leprêtre; Mary M Hulihan; Jennifer Kachergus; Austen J Milnerwood; Lucia Tapia; Mee-Sook Song; Emilie Le Rhun; Eugénie Mutez; Lydie Larvor; Aurélie Duflot; Christel Vanbesien-Mailliot; Alexandre Kreisler; Owen A Ross; Kenya Nishioka; Alexandra I Soto-Ortolaza; Stephanie A Cobb; Heather L Melrose; Bahareh Behrouz; Brett H Keeling; Justin A Bacon; Emna Hentati; Lindsey Williams; Akiko Yanagiya; Nahum Sonenberg; Paul J Lockhart; Abba C Zubair; Ryan J Uitti; Jan O Aasly; Anna Krygowska-Wajs; Grzegorz Opala; Zbigniew K Wszolek; Roberta Frigerio; Demetrius M Maraganore; David Gosal; Tim Lynch; Michael Hutchinson; Anna Rita Bentivoglio; Enza Maria Valente; William C Nichols; Nathan Pankratz; Tatiana Foroud; Rachel A Gibson; Faycal Hentati; Dennis W Dickson; Alain Destée; Matthew J Farrer
Journal:  Am J Hum Genet       Date:  2011-09-09       Impact factor: 11.025

2.  Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.

Authors:  João Paulo L Daher; Olga Pletnikova; Saskia Biskup; Alessandra Musso; Sandra Gellhaar; Dagmar Galter; Juan C Troncoso; Michael K Lee; Ted M Dawson; Valina L Dawson; Darren J Moore
Journal:  Hum Mol Genet       Date:  2012-02-21       Impact factor: 6.150

Review 3.  Regulation of autophagy by lysosomal positioning.

Authors:  Viktor I Korolchuk; David C Rubinsztein
Journal:  Autophagy       Date:  2011-08-01       Impact factor: 16.016

4.  Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.

Authors:  Xianting Li; Jyoti C Patel; Jing Wang; Marat V Avshalumov; Charles Nicholson; Joseph D Buxbaum; Gregory A Elder; Margaret E Rice; Zhenyu Yue
Journal:  J Neurosci       Date:  2010-02-03       Impact factor: 6.167

5.  The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.

Authors:  Tatsunori Maekawa; Sayuri Mori; Yui Sasaki; Takashi Miyajima; Sadahiro Azuma; Etsuro Ohta; Fumiya Obata
Journal:  Mol Neurodegener       Date:  2012-04-25       Impact factor: 14.195

6.  Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Authors:  Byoung Dae Lee; Joo-Ho Shin; Jackalina VanKampen; Leonard Petrucelli; Andrew B West; Han Seok Ko; Yun-Il Lee; Kathleen A Maguire-Zeiss; William J Bowers; Howard J Federoff; Valina L Dawson; Ted M Dawson
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

7.  LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice.

Authors:  Martin C Herzig; Carine Kolly; Elke Persohn; Diethilde Theil; Tatjana Schweizer; Thomas Hafner; Christine Stemmelen; Thomas J Troxler; Peter Schmid; Simone Danner; Christian R Schnell; Matthias Mueller; Bernd Kinzel; Armelle Grevot; Federico Bolognani; Martina Stirn; Rainer R Kuhn; Klemens Kaupmann; P Herman van der Putten; Giorgio Rovelli; Derya R Shimshek
Journal:  Hum Mol Genet       Date:  2011-08-09       Impact factor: 6.150

8.  GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.

Authors:  Klodjan Stafa; Alzbeta Trancikova; Philip J Webber; Liliane Glauser; Andrew B West; Darren J Moore
Journal:  PLoS Genet       Date:  2012-02-09       Impact factor: 5.917

9.  A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan.

Authors:  Hon-Chung Fung; Chiung-Mei Chen; John Hardy; Andrew B Singleton; Yih-Ru Wu
Journal:  BMC Neurol       Date:  2006-12-22       Impact factor: 2.474

10.  Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers.

Authors:  Laura Civiero; Renée Vancraenenbroeck; Elisa Belluzzi; Alexandra Beilina; Evy Lobbestael; Lauran Reyniers; Fangye Gao; Ivan Micetic; Marc De Maeyer; Luigi Bubacco; Veerle Baekelandt; Mark R Cookson; Elisa Greggio; Jean-Marc Taymans
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

View more
  70 in total

1.  CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.

Authors:  David A Loeffler; Lynnae M Smith; Mary P Coffey; Jan O Aasly; Peter A LeWitt
Journal:  J Neural Transm (Vienna)       Date:  2015-11-03       Impact factor: 3.575

Review 2.  Selective neuronal vulnerability in Parkinson disease.

Authors:  D James Surmeier; José A Obeso; Glenda M Halliday
Journal:  Nat Rev Neurosci       Date:  2017-01-20       Impact factor: 34.870

3.  Regulation of a distinct activated RIPK1 intermediate bridging complex I and complex II in TNFα-mediated apoptosis.

Authors:  Palak Amin; Marcus Florez; Ayaz Najafov; Heling Pan; Jiefei Geng; Dimitry Ofengeim; Slawomir A Dziedzic; Huibing Wang; Vica Jean Barrett; Yasushi Ito; Matthew J LaVoie; Junying Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-11       Impact factor: 11.205

4.  LRRK2 mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10.

Authors:  Fieke Wauters; Tom Cornelissen; Dorien Imberechts; Shaun Martin; Brianada Koentjoro; Carolyn Sue; Peter Vangheluwe; Wim Vandenberghe
Journal:  Autophagy       Date:  2019-04-19       Impact factor: 16.016

Review 5.  iPS cells in the study of PD molecular pathogenesis.

Authors:  Melanie M Cobb; Abinaya Ravisankar; Gaia Skibinski; Steven Finkbeiner
Journal:  Cell Tissue Res       Date:  2017-12-12       Impact factor: 5.249

Review 6.  Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers.

Authors:  Alexander G Thompson; Elizabeth Gray; Sabrina M Heman-Ackah; Imre Mäger; Kevin Talbot; Samir El Andaloussi; Matthew J Wood; Martin R Turner
Journal:  Nat Rev Neurol       Date:  2016-05-13       Impact factor: 42.937

7.  LRRK2: An Emerging New Molecule in the Enteric Neuronal System That Quantitatively Regulates Neuronal Peptides and IgA in the Gut.

Authors:  Tatsunori Maekawa; Hitomi Shimayama; Hiromichi Tsushima; Fumitaka Kawakami; Rei Kawashima; Makoto Kubo; Takafumi Ichikawa
Journal:  Dig Dis Sci       Date:  2017-02-06       Impact factor: 3.199

Review 8.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

9.  LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity.

Authors:  Senthilkumar S Karuppagounder; Yulan Xiong; Yunjong Lee; Maeve C Lawless; Donghyun Kim; Emily Nordquist; Ian Martin; Preston Ge; Saurav Brahmachari; Aanishaa Jhaldiyal; Manoj Kumar; Shaida A Andrabi; Ted M Dawson; Valina L Dawson
Journal:  J Chem Neuroanat       Date:  2016-01-22       Impact factor: 3.052

10.  Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice.

Authors:  Yulan Xiong; Stewart Neifert; Senthilkumar S Karuppagounder; Qinfang Liu; Jeannette N Stankowski; Byoung Dae Lee; Han Seok Ko; Yunjong Lee; Jonathan C Grima; Xiaobo Mao; Haisong Jiang; Sung-Ung Kang; Deborah A Swing; Lorraine Iacovitti; Lino Tessarollo; Ted M Dawson; Valina L Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.